Literature DB >> 17452980

hAda3 regulates p14ARF-induced p53 acetylation and senescence.

P Sekaric1, V A Shamanin, J Luo, E J Androphy.   

Abstract

Acetylation is thought to be a key event for p53 activation. We demonstrate that p14ARF-induced senescence of human mammary epithelial cells (MEC) is associated with p53 acetylation and requires hAda3, a component of histone acetyltransferase complexes and a p53 transcriptional coactivator. Expression of the N-terminal domain of hAda3 that binds p53 but not p300 blocked p14ARF-induced p53 acetylation and protected MECs from senescence. Consistent with these findings, the human papillomavirus 16 E6 mutant Y54D, which selectively targets hAda3 but not p53 for degradation and protects MECs from p14ARF-induced senescence, inhibited p53 acetylation. In H1299 cells, hAda3 overexpression increased p300-mediated p53 acetylation, which conversely decreased following small interfering RNA (siRNA) knockdown of hAda3. Moreover, depletion of hAda3 by siRNA inhibited endogenous p53 acetylation and accumulation of p21cip1 in response to ectopic p14ARF. These studies reveal that, in addition to its known ability to inhibit Mdm2-mediated p53 degradation, p14ARF signals through hAda3 to stimulate p53 acetylation and the induction of cell senescence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452980     DOI: 10.1038/sj.onc.1210462

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

2.  The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.

Authors:  Jayashree Thatte; Paola Massimi; Miranda Thomas; Siaw Shi Boon; Lawrence Banks
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 3.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

4.  Cytosine methylation dysregulation in neonates following intrauterine growth restriction.

Authors:  Francine Einstein; Reid F Thompson; Tushar D Bhagat; Melissa J Fazzari; Amit Verma; Nir Barzilai; John M Greally
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

5.  Dual regulation of TERT activity through transcription and splicing by DeltaNP63alpha.

Authors:  Esther Vorovich; Edward A Ratovitski
Journal:  Aging (Albany NY)       Date:  2008-12-09       Impact factor: 5.682

6.  Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT.

Authors:  Pedja Sekaric; Jonathan J Cherry; Elliot J Androphy
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 7.  Critical pathways in cellular senescence and immortalization revealed by gene expression profiling.

Authors:  A L Fridman; M A Tainsky
Journal:  Oncogene       Date:  2008-08-18       Impact factor: 9.867

8.  hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells.

Authors:  Vladimir A Shamanin; Pedja Sekaric; Elliot J Androphy
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

9.  Genomic instability: Ada3 and HPV E6-acetyltransferase connections?

Authors:  Elliot J Androphy
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

10.  CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Authors:  Ranjan Chrisanthar; Stian Knappskog; Erik Løkkevik; Gun Anker; Bjørn Østenstad; Steinar Lundgren; Elisabet O Berge; Terje Risberg; Ingvil Mjaaland; Lovise Maehle; Lars Fredrik Engebretsen; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.